Intracellular penetration and activity of fluoroquinolones;Penetracion y actividad intracelular de las fluoroquinolonas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 16, Issue 3, 1998, Pages 138-143

  Pascual, Álvaro ^a,b   García, Isabel ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DEXTRO OFLOXACIN; FLEROXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMETABOLITE; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; BRUCELLA; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; COXIELLA BURNETII; DRUG PENETRATION; ESCHERICHIA COLI; HEPATOMA CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LEGIONELLA PNEUMOPHILA; LISTERIA MONOCYTOGENES; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; PERITONEUM MACROPHAGE; PHAGOCYTE; POLYMORPHONUCLEAR CELL; PSEUDOMONAS AERUGINOSA; RICKETTSIA; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; BACTERIUM; BIOAVAILABILITY; DRUG EFFECT; EUKARYOTIC CELL; INTRACELLULAR FLUID; METABOLISM; PH; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

ANTI-INFECTIVE AGENTS; ANTIMETABOLITES; BACTERIA; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; EUKARYOTIC CELLS; FLUOROQUINOLONES; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR FLUID; PHAGOCYTES;

EID: 0032012427     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (65)

1. Buggy BP, Schaberg DR, Swartz RD. Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambualtory peritoneal dialysis. Am J Med 1984; 76: 1.035-1.040.
2. Jones RB, Van der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1977; 39 (Supl B): 63-65.
3. Van Landuyt HW, Magerman K, Gordts B. The importance of the quinolones in antibacterial therapy. J Antimicrob Chemother 1990; 26 (Supl D): 1-6.
4. Piddock LJV. New quinolones and gram positive bacteria. Antimicrob Agents Chemother 1994; 38: 163-169.
5. Cruciani M, Basctti D.The fluoroquinolones as treatment for infections caused by gram positive bacteria. J Antimicrob Chemother 1994; 33: 403-417.
6. Kojima T, Inoue M, Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother 1989; 33: 1.980-1.988.
7. Child SI, Ander J, Boswell F, Brenwald N, Wise R. The in vitro activity of CP 99-219, a new naphtyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869-876.
8. Klempner MS, Styrt B. Clindamycin uptake by human neutrophils. J Infect Dis 1981; 144: 472-475.
9. Hand WL, King-Thompson NL. Membrane transport of clindamycin in alveolar macrophages. Antimicrob Agents Chemother 1982; 21: 241-247.
10. Pascual A, Tsukayama D, Kovarik J, Gekker G, Peterson PK. Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. Eur J Clin Microbiol 1987; 6: 152-157.
11. Koga H. High performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother 1987; 31: 1.904-1.908.
12. Pascual A, García I, Perea EJ. Fluorometric measurement of ofloxacin uptake ty human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1989; 33: 653-656.
13. Easmon CSF, Crane JP. Uptake of ciprofloxacin by macrophages. J Clin Pathol 1985; 38: 442-444.
14. Van der Auwera P, Matsumoto T, Husson M. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother 1988; 22: 185-192.
15. Pascual A, García I, Conejo MC, Perea EJ. Fluorometric and high performance liquid chromatographic measurement of quinolone uptake by human neutrophils. Eur J Clin Microbiol Infect Dis 1991; 10: 969-971.
16. García I, Pascual A, Guzmán MC, Perea EJ. Uptake and intracellullar activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother 1992; 36: 1.053-1.056.
17. Pascual A, García I, Ballesta S, Perea EJ. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1997; 41: 274-277.
18. Tulkens PM. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 100-107.
19. Smith DL, Rommel F. A rapid micro method for the simultaneous determination of phagocytic-microbicidal activity of human peripheral blood leukocytes in vitro. J Immunol Methods 1977; 17: 214-247.
20. Vosbevck K, James PR, Zimmerman W. Antibiotic action of phagocytosed bacteria measured by a new method for determining viable bacteria. Antimicrob Agents Chemother 1984; 25: 735-741.
21. Peterson PK, Verhoef J, Schetig D, Quie PG. Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes. J Infect Dis 1977; 136: 502-509.
22. Pascual A, García I, Perea EJ. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother 1990; 34: 277-280.
23. Perea EJ, García I, Pascual A. Comparative penetration of lomefloxacin with other quinolones into human phagocytes. Amer J Med 1992; 92 (Supl 4A): 48-51.
24. Pascual A, García I, Perea EJ. Entry of lomefloxacin and temafloxacin into human neutrophils, peritoneal macrophages and tissue culture cells. Diagnost Microbiol Infect Dis 1992; 15: 385-392.
25. García I, Pascual A, Perea EJ. Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1994; 38: 2.426-2.429.
26. Ballesta S, Pascual A, García I, Perea EJ. Penetración de cinco fluoroquinolonas en polimorfonucleares humanos. Enferm Microbiol Clin 1996; 14: 470-473.
27. Pascual A, García I, Ballesta S, Perea EJ. Uptake and intracellular activity of BAY 12-8039 in human neutrophils and tissue-cultured epithelial cells. Program Abstract Interscience Conference of Antimicrobial Agents and Chemotherapy, 1997 [resumen F-149].
28. McDonald PJ, Pruul, H. Phagocyte uptake and transport of azitrhomycin. Eur J Clin Microbiol Infect Dis 1991; 10: 828-833.
29. Pascual A, García I, Perea EJ. Effect of antimicrobial agents on the uptake of ofloxacin and its optically active isomer (-)-ofloxacin by human polymorphonuclear leukocytes. J Antimicrob Chemother 1991; 28: 727-730.
30. Pascual A, García I, Conejo MC, Perea EJ. Effects of antimicrobial and antineoplastic drugs on the uptake of sparfloxacin by human neutrophils. J Antimicrob Chemother 1994; 34: 171-174.
31. García I, Pascual A, Salvador J, Conejo MC, Perea EJ. Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. J Antimicrob Chemother 1996; 38: 859-863.
32. Gladue RP, Snider ME. Intracellular accumulation of azitromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34: 1.056-1.060.
33. García I, Pascual A, Conejo MC, Perea EJ. Penetración intracelular de cinco quinolonas en células no fagocíticas. Enferm Infecc Microbiol Clin 1996; 14: 167-170.
34. Piddock LJV, Jin YF. Activity and accumulation of BAY 12-8039. Program Abstract Interscience Conference of Antimicrobial Agents and Chemotherapy, 1997 [resumen F-127].
35. Easmon CSF, Crane JP. Uptake of ciprofoxacin by human neutrophils. J Antimicrob Chemother 1985; 16: 67-73.
36. Carlier MB, Scorneaux B, Zenebergh A, Desnotted JF, Tulkens PM. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26 (Supl B): 27-39.
37. Carlier MB, Scorneaux B, Tulkens PM. Uptake and subcellular localization of sparfloxacin (AT-4140, RP-64206; S) in phagocytic cells. Program Abstract Interscience Conference of Antimicrobial Agents and Chemotherpay 1990 [resumen 1.243].
38. Taira K, Koga H, Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1993; 37: 1.877-1.881.
39. Memin E, Panteix G, Revol A. Is the uptake of pefloxacin in human blood monocytes a simple diffusion process? J Antimicrob Chemother 1996; 38: 787-798.
40. Ozaki M, Komori K, Matsuda M, Yamaguchi R, Honmura T, Tomii Y et al. Uptake and intracellular activity of NM394, a new quinolone in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1996; 40: 739-742.
41. Yamamoto T, Kusajima H, Hosaka M, Fukuda H, Oomori Y, Shinoda H. Uptake and intracellular activity of AM-1155 in phagocytic cells. Antimicrob Agents Chemother 1996; 40: 2.756-2.759.
42. Memin E, Panteix G, Revol A. Barrier-mediated system for pefloxacin uptake in human monocytes. J Antimicrob Chemother 1997; 40: 263-268.
43. Renard C, Vander Haegue HC, Claes PJ, Zenebergh A, Tulkens PM. Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. Antimicrob Agents Chemother 1987; 31: 410-416.
44. Hands WL, King-Thompson NL. Contrast between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity. Antimicrob Agents Chemother 1986; 29: 135-140.
45. Ballesta S, Pascual A, García I, Conejo MC, Perea EJ. Efecto de cinco fluoroquinolonas en la actividad bactericida de los leucocitos polimorfonucleares humanos contra Staphylococcus aureus. Enferm Infecc Microbiol Clin 1996; 14: 600-603.
46. Anderson R, Jooné GK. In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (C1-960) and PD 131628. Chemother 1993; 39: 424-431.
47. Pemán J, Canton E, Hernández MT, Gobernado M. Intraphagocytic killing of gram positive bacteria by ciprofloxacin. J Antimicrob Chemother 1994; 34: 965-974.
48. Yamamoto T, Kusajima H, Hosaka M, Shinoda H. Uptake and intracellular activity of fleroxacin in phagocytic cells. Chemother 1995; 41: 353-359.
49. Beam TR. Sequestration of staphylococci at an inaccesible focus. Lancet 1979; 2: 227-228.
50. Cantón E, Jiménez T, Pemán J, Ramón MS, Gobernado, M. Intraphagocytic bioactivity of lomefloxacin against Pseudomonas aeruginosa. J Antimicrob Chemother 1993; 32: 279-284.
51. Phanucharas JP, Gorby GL. Differential intracellualr efficacies of ciprofloxacin and cefixime against Neisseria gonorrhoeae in human fallopian tube organ culture. Antimicrob Agents Chemother 1997; 41: 1.547-1.551.
52. Perea EJ, Aznar J, Herrera A, Mazuecos J, Rodriguez Pichardo A. Clinical efficacy of new quinolones for therapy of nongonococcal urethritis. Sex Trans Dis 1989; 16: 7-10.
53. Maurin M, Raoult D. Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, «Israeli spotted fever group rickettsia» and Coxiella burnetii. J Antimicrob Chemother 1997; 39: 725-730.
54. Nichterlein T, Kretschmar M, Budeanu C, Bauer J, Linss W, Hof H. BAY Y 3118, a new quinolone derivative, rapidly erradicates Listeria monocytogenes from infected mice a L929 cells. Antimicrob Agents Chemother 1994; 38: 1.501-1.506.
55. Michelet C, Avril JL, Arvieux C, Jacquelinet C, Vu N, Cartier F. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethroprim-sulfametoxazole, or rifampin, against intracellular Listeria monocytogenes. Antimicrob Agents Chemother 1997; 41: 60-65.
56. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ. Activities of sparfloxacin, azitrhomycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991; 35: 1.356-1.359.
57. Tomioka H, Saito H, Sato K Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1.259-1.263.
58. Mor N, Vanderkolk J, Heifeits L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38: 1.161-1.164.
59. Furet YX, Pechere JC. Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis 1991; 4: 249-254.
60. Walz A, Nichterlein T, Hof H. Excellent activity of newer quinolones on Legionella pneumophila in J774 macrophages. Zentralbl Bakteriol 1997; 285: 431-439.
61. Dubois J, St. Pierre C. An in vitro susceptibility study of trovafloxacin against Legionella spp. Program Abstract interscience Conference of Antimicrobial Agents and Chemotherapy, 1996 [resumen E75].
62. Millas E, Lázaro MA, Bermejo M, Gimeno C, Sánchez S, García de Lomas J. In vitro activity of trovafloxacin (CP-116,517) against Legionella pneumophila in an experimental guinea pig pneumonia model. Program Abstract Interscience Conference of Antimicrobial Agents and Chemotherapy, 1996 [resumen E76].
63. Pechere JC. Quinolones in intracellular infections. Drugs 1993; 45 (Supl 3): 29-36.
64. Sangari FJ, Aguero J. Mollecular basis of Brucella pathogenicity: an update. Microbiologia 1996; 12: 207-218.
65. Corbel MJ. Brucellosis: an overview. Emerg Infect Dis 1997; 3: 213-221.